Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Recruiting · NCT06819735 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06819735 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Domain Therapeutics Australia Pty Ltd | 1 |
| Domain Therapeutics SA | 2 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cabrini Health Limited | Malvern | Australia | 4 |
| Cancer Research SA | Adelaide | Australia | 18 |
| Honor Health Research Institute | Scottsdale | United States | 17 |
| Hôpitaux Universitaires de Strasbourg | Strasbourg | France | 7 |
| Institut Bergonié | Bordeaux | France | 53 |
| Institut Gustave Roussy | Villejuif | France | 54 |
| Macquarie University Clinical Trial Unit | North Ryde | Australia | 1 |
| One Clinical Research Pty Ltd | Nedlands | Australia | 3 |
| Peninsula & South Eastern Haematology & Oncology Group | Frankston | Australia | 2 |